Edward A ONeill
Overview
Explore the profile of Edward A ONeill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nussbaum J, Hussain A, Butera P, Ford A, Kitt M, ONeill E, et al.
J Clin Pharmacol
. 2024 Apr;
64(8):1023-1029.
PMID: 38651193
Gefapixant (MK-7264, RO4926219, AF-219) is a first-in-class P2X3 antagonists being developed to treat refractory or unexplained chronic cough. The initial single- and multiple-dose safety, tolerability, and pharmacokinetics of gefapixant at...
2.
Johns D, Campeau L, Banka P, Bautmans A, Bueters T, Bianchi E, et al.
Circulation
. 2023 May;
148(2):144-158.
PMID: 37125593
Background: Inhibition of PCSK9 (proprotein convertase subtilisin/kexin type 9)-low density lipoprotein receptor interaction with injectable monoclonal antibodies or small interfering RNA lowers plasma low density lipoprotein-cholesterol, but despite nearly 2...
3.
Kaku K, Kadowaki T, Seino Y, Okamoto T, Shirakawa M, Sato A, et al.
Diabetes Obes Metab
. 2021 May;
23(9):2099-2108.
PMID: 34033212
Aims: To assess the efficacy, safety and tolerability of ipragliflozin 50 mg once daily added to sitagliptin 50 mg once daily monotherapy in Japanese patients with type 2 diabetes (T2D)....
4.
Seino Y, Kaku K, Kadowaki T, Okamoto T, Sato A, Shirakawa M, et al.
Diabetes Obes Metab
. 2021 Feb;
23(6):1342-1350.
PMID: 33565686
Aims: To investigate the efficacy, safety and tolerability of sitagliptin 50 mg once daily added to ipragliflozin 50 mg once daily monotherapy in Japanese patients with type 2 diabetes (T2D)....
5.
Kadowaki T, Seino Y, Kaku K, Okamoto T, Kameya M, Sato A, et al.
Diabetes Obes Metab
. 2021 Jan;
23(6):1242-1251.
PMID: 33512755
Aim: To evaluate the efficacy and safety of adding the once-weekly oral dipeptidyl peptidase-4 inhibitor omarigliptin to treatment of Japanese patients with type 2 diabetes and inadequate glycaemic control on...
6.
Raji A, Jin Xu Z, Lam R, ONeill E, Kaufman K, Engel S
Diabetes Ther
. 2020 Aug;
11(10):2419-2428.
PMID: 32852696
Introduction: Older patients with type 2 diabetes (T2D) are at increased risk of diabetic nephropathy and mild renal insufficiency. This analysis compared the anti-hyperglycemic efficacy and safety of sitagliptin with...
7.
Frias J, Zimmer Z, Lam R, Amorin G, Ntabadde C, Iredale C, et al.
Diabetes Obes Metab
. 2019 Jan;
21(5):1128-1135.
PMID: 30609212
Aims: To characterize the glycaemic efficacy and safety of initiation of the dipeptidyl peptidase-4 inhibitor sitagliptin during metformin dose escalation in people with type 2 diabetes (T2D) not at glycated...
8.
Roussel R, Duran-Garcia S, Zhang Y, Shah S, Darmiento C, Shankar R, et al.
Diabetes Obes Metab
. 2018 Nov;
21(4):781-790.
PMID: 30393950
Aims: To compare the effects of continuing versus discontinuing sitagliptin when initiating and intensively titrating insulin glargine. Materials And Methods: Eligible patients had inadequately controlled type 2 diabetes on metformin...
9.
Yu M, Shankar R, Zhang R, Zhang Y, Lin J, ONeill E, et al.
Diabetes Obes Metab
. 2018 Sep;
21(2):408-411.
PMID: 30178570
To improve understanding of the safety and efficacy of adding sitagliptin to treatment of patients with type 2 diabetes taking premixed insulin, data from patients using premixed insulin ± metformin...
10.
Scott R, Morgan J, Zimmer Z, Lam R, ONeill E, Kaufman K, et al.
Diabetes Obes Metab
. 2018 Jul;
20(12):2876-2884.
PMID: 30019498
Aim: To compare the efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin with the sodium-glucose transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes and mild renal insufficiency. Materials...